Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

148.77
+2.031.38%
Post-market: 149.000.2300+0.15%19:58 EDT
Volume:4.63M
Turnover:685.63M
Market Cap:184.58B
PE:-56.89
High:148.94
Open:146.60
Low:145.58
Close:146.74
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.74
T/O Rate:0.37%
Dividend:3.22
Dividend Rate:2.16%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.60
PE(LYR):21.94

Loading ...

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Global Drugmakers Invest Billions to Boost US Presence

Reuters
·
Aug 10

Erasca Appoints Charles Fuchs as President of R&D

Reuters
·
Aug 10

Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target

TIPRANKS
·
Aug 08

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 08

Moderna Inc. Stock Climbs 9.9%, Outperforms Peers

Dow Jones
·
Aug 08

Moderna Inc. Stock Sheds 4.3%, Underperforms Peers

Dow Jones
·
Aug 07

Gilead Sciences (GILD) Stock Price Reflects R And D Shock Not Sales Weakness

Simply Wall St.
·
Aug 06

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Reuters
·
Aug 06

Gilead Sciences Declares Q3 2026 Distribution of R$ 1.42 Per Unit for Brgildbdr 000

Reuters
·
Aug 06

Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says

MT Newswires Live
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Staar Surgical (STAA) and Elanco Animal Health (ELAN)

TIPRANKS
·
Aug 06

Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis

TradingKey
·
Aug 06

Gilead Sciences (GILD) Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation

Simply Wall St.
·
Aug 05

Movement Alert|Gilead Sciences Falls 3.03% in Regular Trading, Q2 Acquisition-Driven R&D Charges Swing Results to Loss Despite Revenue Beat

Market Focus
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating

MT Newswires Live
·
Aug 05

Immuneering Expects Cash Runway to Fund Operations into 2029

Reuters
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Gilead : Leerink Partners Raises Target Price to $130 from $126

THOMSON REUTERS
·
Aug 05